I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive me..:
Swain, Sandra M
;
Miles, David
;
Kim, Sung-Bae
...
The Lancet Oncology, Vol.21 No.4, pp.519-530. , 2020
Link:
https://hdl.handle.net/10371/177224
RT Journal T1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
UL https://suche.suub.uni-bremen.de/peid=base-ftseoulnuniv:oai:s-space.snu.ac.kr:10371_177224&Exemplar=1&LAN=DE A1 Swain, Sandra M A1 Miles, David A1 Kim, Sung-Bae A1 Im, Young-Hyuck A1 Im, Seock-Ah A1 Semiglazov, Vladimir A1 Ciruelos, Eva A1 Schneeweiss, Andreas A1 Loi, Sherene A1 Monturus, Estefania A1 Clark, Emma A1 Knott, Adam A1 Restuccia, Eleonora A1 Benyunes, Mark C A1 Cortes, Javier PB The Lancet Publishing Group YR 2020 K1 PLUS TRASTUZUMAB K1 OPEN-LABEL K1 RECEPTOR K1 SURVIVAL K1 THERAPY K1 SAFETY K1 VINORELBINE K1 COMBINATION K1 EFFICACY K1 HER2 JF The Lancet Oncology, Vol.21 No.4, pp.519-530 LK http://dx.doi.org/https://hdl.handle.net/10371/177224 DO https://hdl.handle.net/10371/177224 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)